Compugen Ltd.
CGEN Healthcare Biotechnology
Compugen Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $72.8 million, up 161.1% from fiscal 2024. In the quarter to June 2026, revenue grew 107.0%, EPS grew 12.5% and free cash flow fell 155.4%, each against the same quarter a year earlier.
Follow CGEN
Compugen Ltd. (CGEN) P/E ratio
As of 15 October 2026, Compugen Ltd. (CGEN) trades at a P/E ratio of 5.5×. Over the past ten years it has ranged from 0.0× (December 2025) to 79.4× (October 2024); the current reading is higher than 93% of that period. That is below the Biotechnology industry median of 8.4× and below the Healthcare sector median of 22.8×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 4.1× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 5.6× | (2.17%) |
| Mar 2026 | 5.8× | 39.22% |
| Dec 2025 | 4.1× | — |
| Sep 2025 | 0.0× | — |
| 20 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| LYEL Lyell Immunopharma, Inc. compare | n/m |
| ELDN Eledon Pharmaceuticals, Inc. compare | n/m |
| SION Sionna Therapeutics, Inc. compare | n/m |
| BCYC Bicycle Therapeutics PLC Sponsored ADR compare | n/m |
| UPB Upstream Bio, Inc. compare | n/m |
| RNAC Cartesian Therapeutics, Inc. compare | n/m |
| IVVD Invivyd, Inc. compare | n/m |
| ACOG Alpha Cognition Inc. compare | n/m |
| CGEN Compugen Ltd. | 5.5× |
| Biotechnology industry median | 8.4× |
| Healthcare sector median | 22.8× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)